Appointment to the Board of Directors of Alzprotect (Lille, December 5, 2024).
Dr Philippe Verwaerde (CEO of Alzprotect) announced the appointment of Prof. Christian Bailly (#Oncowitan) to the Board of Directors of Alzprotect (Lille, France) to contribute to the development of their drug candidate AZP2006 (Ezeprogind) for the treatment of progressive supranuclear palsy (PSP).